Clinical Trials at Ingalls Memorial
Our goal is to provide the highest level of care to all of our patients, and that includes offering novel treatments before they are widely available. If you are a cancer patient, you may be eligible for one of our current clinical trials.
Bile Duct Cancer
- Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib vs Physician’s Choice in Subjects with FGFR-altered, Chemotherapy and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Bladder Cancer
- Stage II or Stage III
- A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Breast Cancer
- Stage I-IIIC
- The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- Stage I-III
- Optimizing Endocrine Therapy through Motivational Interviewing and Text Interventions
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage II-III
- OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I
- A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Early Stage
- Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- The GLORIA Study: A Phase III, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI 822)/OBI 821 in the Adjuvant Treatment of Patients with High Risk Early Stage Globo H-Positive Triple Negative Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- Title Randomized Phase II Study of Sacituzumab Govitecan with or without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage II or Stage III
- A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase 1 Pilot Study with Dose Expansion of Chemotherapy in Combination with CD40 Agonist and Flt3 Ligand in Metastatic Triple Negative Breast Cancer (SCCC-03121)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I-III
- A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Stage I-III
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 Inhibitor Therapy (OPERA-01)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Randomized, Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, and Treatment of Physician’s Choice in Patients with AR+ Metastatic Triple-Negative or ER-Low Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab- paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TROPION -Breast05)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast CancerOptimizing Endocrine Therapy through Motivational Interviewing and Text Interventions
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Early Stage
- A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-Negative Recurrent or Metastatic Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Colon/Rectal Cancer
- Stage II or III
- The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients with Locally Advanced Rectal Cancer.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage II or Stage III
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Stage IV
An Open-Label, Multicenter, Randomized Phase 3 Study of First-Line Encorafenib Plus Cetuximab with or without Chemotherapy Versus Standard of Care Therapy with a Safety Lead-In of Encorafenib and Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer.
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- T4N0 or Stage III
- A Phase III, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Gastric Cancer (Stomach Cancer)
- Randomized Phase III Trial of MFolfirinox +/- Nivolumab vs. Folfox +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IB - IIIC
- PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-Deletion
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Gynecologic Cancer
- Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer (AFT-50 - Endomap)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase 1/2 Study of REGN5668 (MUC16 X CD28, a Costimulatory Bispecific) Administered in Combination with Cemplumab or REGN4018 (MUC16 X CD3)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- GoG-3078 Randomized, Multicenter, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine in Combination with Bevacizumab versus Bevacizumab Alone as Maintenance Therapy for Patients with FRα-Positive Recurrent Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed after Second Line Platinum-Based Chemotherapy Plus Bevacizumab.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- RT-PACE: Phase I/II Study of Adjuvant Whole Pelvic Hypofractionated Radiotherapy for Non-Metastatic Cervical and Endometrial Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Head and Neck Cancer
- Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma that have Progressed after Platinum Treatment and Immunotherapy.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- TARGET HPV: A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination with Neoadjuvant Chemotherapy followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II Study of Pembrolizumab in Combination with Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY trial (Squamous cell carcInoma of head and NEck Response-Guided therapY)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II Study of Adjuvant Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Salivary Gland Carcinomas.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage III-IV
- Pilot Study of Induction Therapy Followed by Response-Adaptive Treatment and Dynamic Changes in Circulating Tumor DNA in Locoregionally Advanced HPV Negative Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab Versus Pembrolizumab in First-Line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 3 Open-Label Randomized Controlled Study to Evaluate Efficacy and Safety of Petosemtamab Compared with Investigator’s Choice Monotherapy Tx in Previously Treated Patients with Incurable Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Kidney Cancer
- Stage IV
- A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Leukemia
- Stage I - IV
- Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Liver Cancer
- An Open-Label, Prospective, Multi-Center, Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphereTM Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC) (ROWAN)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients with Advanced Hepatocellular Carcinoma (ITER-002-HCC)
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
BCLC Stage B or C
Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects Who Have Not Previously Received Systemic Treatment – LIVIGNO-2.
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
Lung Cancer
- Stage IIIB-IV
- Study Title A Phase 1B Study of Venetoclax in Combination with Pembrolizumab in Subjects with Previously Untreated Non-Small Cell Lung Cancer Whose Tumors have High PD-L1 Expression
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IIIB-C or Stage IV
- A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- Randomized Phase 3 Study of Combination AZD9291 (Osimertinib) and Bevacizumab versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- Master Protocol to Evaluate Biomarker-Drive Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I-II
- Phase III Randomized Placebo-Controlled Double-Blind Multi-Center International Study of Durvalumab with Stereotactic Body Radiation Therapy for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II Trial of Durvalumab (MEDI4736) and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 2, Multicenter, Randomized, Open-Label Study of DS-7300A, A B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I-III
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1).
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- Stage IIIB-IIIIC or Stage IV
- A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line Treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase Ib/IIa Safety and Tolerability Study of Bemcentinib with Pembrolizumab/ Carboplatin/ Pemetrexed in Subjects with Untreated Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) without/with a STK11 Mutation
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Lymphoma
- Stage I - IV
- Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase I/II Study of Acalabrutinib, Venetoclax and Obinutuzimab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Multiple Myeloma
- High-Risk SMM
- Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II Study of Belantamab Mafodotin in Combination with Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients with Relapsed Multiple Myeloma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Neuroendocrine Tumors
- Stage IV
- A Randomized Phase II/III Trial of First Line Platinum/ Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Pancreas Cancer
- Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel / Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with Avutometinib (VS-6766) and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Prostate Cancer
- A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients with High-Risk Localized Prostate Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- ProsGATE: Geriatric Assessment and Technology Evaluation in Prostate cancer.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III Randomized, Open-Label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Solid Tumors and Multiple Disease Sites
- Molecular Analysis for Combination Therapy Choice (ComboMATCH).
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage III or Stage IV
- An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-Expressing Tumors (DESTINY-PanTumor02)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase I/IIa Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-Expressing Cancers.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase I Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors (DB-1303-O-1001).
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
Study Title An Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations.
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- A Phase Ia, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1).
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- A Phase I/II Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IIB, IIIC, or Stage IV
- A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Advanced Stage
- A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination with Olaparib or Durvalumab in Patients with Selected Solid Tumor Malignancies
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- • A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
Biobanking
- Protocol for Lymphoma Program Biobank
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
- Any Stage
- Genomic Analysis to Identify Correlates of the Inflamed Tumor-Phenotype in Patients with Advanced Malignancies Receiving Immunotherapy
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.